Harry Sloan - 12 Jun 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol
DNA
Transactions as of
12 Jun 2024
Net transactions value
$0
Form type
4
Filing time
14 Jun 2024, 16:35:56 UTC
Previous filing
14 May 2024
Next filing
14 Jun 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Harry Sloan filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 14 Jun 2024."

Quick Takeaways

  • This page summarizes Harry Sloan's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
  • 4 reported transactions and 3 derivative rows are listed below.
  • Filing timestamp: 14 Jun 2024, 16:35.

What Changed

  • Previous filing in this sequence was filed on 14 May 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +105,263 +15% 823,803 12 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -105,263 -100% 0 12 Jun 2024 Class A Common Stock 105,263 $0.000000 Direct F1, F2
transaction DNA Restricted Stock Units Award $0 +432,900 $0.000000 432,900 13 Jun 2024 Class A Common Stock 432,900 $0.000000 Direct F1, F3
transaction DNA Stock Option Award $0 +571,428 $0.000000 571,428 13 Jun 2024 Class A Common Stock 571,428 $0.4620 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
F3 The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
F4 In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.

Sponsored